2025 Eating-Disorder Review Finds a Very Small Psilocybin Evidence Base

A systematic review published on July 29, 2025, highlights how early psilocybin research for eating disorders remained within its search window. The authors found only two published studies meeting their criteria, plus six registered clinical trials. The review in Eating and Weight Disorders is a map of a developing field, not evidence that psilocybin is an established eating-disorder treatment.

What the authors searched

The researchers searched PubMed, EMBASE, and the Cochrane Library for original research involving psilocybin and eating disorders. Their literature search extended through July 29, 2024. They also searched ClinicalTrials.gov to identify registered studies. That combination allowed them to describe both published observations and research being planned or conducted.

The search date is essential to interpreting the article. Although the review appeared in 2025, its published-study evidence does not represent everything that might emerge during 2025 or 2026. It should be described as a dated assessment of the literature, rather than a permanent statement that only two studies exist.

What counted as published evidence

One included study was an open-label feasibility investigation involving 10 individuals with anorexia nervosa, without a control group. The other was a single case report involving a person with anorexia nervosa. Those designs can generate questions and describe experiences, but they provide limited protection against alternative explanations for apparent improvement.

In an uncontrolled study, changes could reflect the intervention, accompanying support, expectations, other care, or variation over time. A case report offers even less basis for generalizing to other patients. Neither design supplies the same evidence about comparative effectiveness as a well-conducted randomized trial.

Why feasibility is not efficacy

Feasibility research asks whether an intervention and its procedures can be carried out in a selected population. It can help researchers refine recruitment, assessment, monitoring, and follow-up. A favorable feasibility finding does not establish that the intervention improves the disorder more than a comparison treatment.

That distinction can disappear when an early study reaches a headline. A statement that a treatment was possible to deliver may become a claim that it works. The review's limited evidence base calls for the opposite approach: describe exactly what was studied, what changed, and which causal questions remain unanswered.

Registered studies are not completed results

The six registered trials identified by the review show scientific activity. They do not constitute six additional demonstrations of benefit. Registration documents what investigators intend to study, while results are needed to determine what actually happened. Protocols, recruitment, completed follow-up, and peer-reviewed findings are different stages.

For patients encountering trial announcements, that means an invitation to participate should not be interpreted as an offer of a proven therapy. The NIH clinical-trials guide explains that research is designed to answer questions and does not guarantee personal benefit. That framework applies even when the rationale for a study sounds compelling.

What stronger evidence would need to address

• Comparison: Does the intervention outperform an appropriate control condition?
• Clinical outcomes: Are changes relevant to the eating disorder, not only attitudes toward the experience?
• Durability: Do any benefits persist beyond the immediate follow-up?
• Safety: How are medical and psychological problems assessed and reported?
• Generalizability: Which patients were excluded, and whom do the results actually represent?

These questions should guide interpretation rather than be treated as reasons to dismiss the field. Early research can be worth doing precisely because an important clinical question remains unanswered. The responsibility is to preserve that uncertainty while investigators work toward more informative evidence.

The review's central message is therefore modest but useful: there was enough preliminary work to justify further investigation, but far too little published controlled evidence within its search window to support confident treatment claims. Research participation and established clinical care should not be confused, and ongoing care should not be displaced by enthusiasm for an unproven approach.

Sources

• Eating and Weight Disorders: 2025 systematic review
• NIH: Clinical Trials and You—The Basics